This revised report reorganises the main details around Jesy Nelson’s SMA Screening Campaign: From April Breakthrough to England-Wide Rollout for clearer reading while preserving the original article’s factual content.
Former Little Mix singer Jesy Nelson celebrated a major milestone in April 2026 when the government confirmed that newborn screening for spinal muscular atrophy would begin in England earlier than originally planned.
Nelson had become a prominent campaigner for newborn SMA screening after her twin daughters, Ocean Jade and Story Monroe Nelson, were diagnosed with the rare inherited condition.
The April announcement brought the start of an NHS in-service evaluation forward from January 2027 to October 2026.
But the story continued. The initial plan would not immediately cover every newborn screening laboratory in England, leading Nelson and other campaigners to warn about a postcode lottery.
In July, the Department of Health and Social Care announced that the evaluation would be expanded across England, with implementation continuing through 2027.
What is spinal muscular atrophy?
Spinal muscular atrophy, usually shortened to SMA, is a rare inherited neuromuscular condition.
It affects motor neurons, the nerve cells involved in controlling voluntary muscle movement.
The condition can cause progressive muscle weakness and may affect movement, swallowing and breathing.
The severity varies between people and depends partly on the form of SMA involved.
Why early diagnosis matters
SMA can begin causing irreversible loss of motor function before a child has obvious symptoms.
Modern disease-modifying treatments have changed the outlook for affected children, particularly when treatment can begin very early.
This is the central argument for newborn screening: identify affected babies before significant symptoms develop so they can be assessed rapidly by specialist clinicians.
Screening is not itself treatment or a definitive diagnosis. Babies with a positive screening result need appropriate confirmatory testing and specialist care.
Why Jesy Nelson became involved
Nelson’s campaign was shaped by her family’s experience after her twins were diagnosed with SMA.
She used interviews, social media and a public petition to argue that newborn babies should have access to screening as part of the routine heel-prick blood test.
Her campaign attracted more than 100,000 signatures and helped bring additional public attention to a long-running issue for SMA charities and medical specialists.
What was announced in April 2026?
Health Secretary Wes Streeting confirmed that the planned in-service evaluation would begin in October 2026 rather than January 2027.
The three-month acceleration was welcomed by Nelson and SMA UK.
At the time, Nelson described the decision as a major milestone for the SMA community.
The NHS evaluation was designed to test how SMA screening would work in real newborn-screening services and gather evidence about effectiveness, feasibility and cost.
What is an in-service evaluation?
An in-service evaluation, or ISE, allows the NHS to test a proposed screening programme in routine clinical settings while collecting evidence.
The UK National Screening Committee had identified remaining evidence questions around population-wide SMA screening.
Rather than waiting for perfect evidence from outside the NHS, the ISE was intended to generate practical information through real-world delivery.
The findings can then inform future recommendations about permanent screening policy.
How does the newborn heel-prick test work?
The newborn blood spot test is normally offered shortly after birth.
A small blood sample is collected from a baby’s heel and used to screen for a number of rare but serious conditions.
Adding SMA means laboratory analysis can look for the genetic pattern associated with the disease as part of that broader screening pathway.
Parents should rely on NHS guidance and clinical teams for information about consent, results and follow-up.
Why the initial rollout caused concern
The first phase was planned around seven newborn screening laboratories that already had equipment suitable for beginning SMA screening.
That meant the evaluation would initially cover only part of England.
Campaigners argued that a baby’s chance of receiving early screening should not depend on where the family lived.
Nelson later described the partial rollout as a postcode lottery.
Why the postcode issue mattered medically
For a condition that can progress rapidly, delays in diagnosis can affect treatment opportunities and outcomes.
This made geographic variation particularly controversial.
Campaigners argued that families in areas outside the first evaluation sites could continue receiving diagnoses only after symptoms appeared, while babies elsewhere might be identified at birth.
The government said it was examining how to extend the evaluation further.
What happened in June?
The campaign continued after the April announcement.
A petition calling for faster and broader SMA screening attracted around 150,000 signatures and was debated in Parliament.
Nelson publicly argued that partial coverage was not enough.
Health officials continued working on options for expanding the programme to additional laboratories.
The July national expansion
On 16 July, the government announced that the SMA newborn screening evaluation would be expanded throughout England.
Hundreds of thousands of babies are expected to be screened as the programme expands.
Testing is scheduled to begin in October 2026 at the laboratories ready to participate first, with implementation continuing through 2027 as the remaining sites are brought into the programme.
The government’s stated goal is for babies across England to have access rather than leaving permanent geographic gaps.
Was this immediately a permanent national screening programme?
The wording requires care.
The government announced an England-wide expansion of an evaluation programme.
The in-service evaluation is intended to generate evidence that will inform future UK National Screening Committee recommendations about longer-term policy.
For families, the practical effect is that access is being expanded widely, but the evidence-gathering purpose of the programme remains important.
Why the programme is being expanded in stages
Newborn screening requires laboratory equipment, trained staff, quality assurance, clinical pathways and systems for rapid referral after a positive result.
It is not simply a matter of adding another box to a laboratory form.
The original seven laboratories were able to begin sooner because they already had relevant equipment.
Bringing the remaining laboratories into the programme requires funding and implementation work.
How is the expansion being funded?
The Department of Health and Social Care said it would seek investment to support broader rollout.
The evaluation itself also receives research funding.
Government and screening bodies have been working with partner organisations to secure the resources needed for expansion.
This funding model is part of the reason implementation occurs over time rather than on a single national start date.
What did Jesy Nelson say after the July announcement?
Nelson described the national expansion as a victory for families affected by SMA and a day of hope.
She emphasised the importance of diagnosing babies before irreversible symptoms develop.
Her response also acknowledged that the change could not alter what had already happened to children diagnosed later, including her own family.
The focus of the campaign was on improving the pathway for babies born in the future.
What role did SMA UK play?
SMA UK and other organisations had campaigned on screening long before Nelson’s involvement.
The charity provided specialist knowledge and worked with families, clinicians and policymakers.
Nelson’s celebrity platform increased public attention, while established patient organisations contributed years of evidence and advocacy.
The policy change is therefore best understood as the result of a wider community campaign rather than the work of one individual alone.
Why newborn screening policy takes time
Screening healthy newborns at population scale requires a high evidence standard.
A screening test needs to identify affected babies accurately while minimising false results and unnecessary anxiety.
Health authorities also need evidence that early identification leads to meaningful benefit and that the programme can be delivered effectively.
This is why the UK National Screening Committee uses formal evidence reviews rather than adding conditions solely because a test exists.
How treatment has changed the screening debate
The availability of disease-modifying therapies has made early identification more valuable.
When there were few effective treatments, finding a condition before symptoms could offer limited clinical benefit.
When treatment can alter disease progression, the timing of diagnosis becomes more important.
This shift has driven international expansion of SMA newborn screening.
What parents should know
Parents should use current NHS information rather than assuming the timing described in an older article applies to their local area.
The rollout is staged, and implementation dates can differ between screening laboratories.
Anyone concerned about a child’s health should seek medical advice rather than wait for or rely solely on a screening programme.
Newborn screening is designed to identify risk early, not replace clinical assessment.
Why the April headline needs the July update
In April, the genuine news was that SMA screening would start earlier than planned.
By June, the limitation of partial geographic coverage had become a major issue.
By July, the government had committed to expanding the evaluation across England.
Leaving the article frozen at the first announcement would miss the most important development in the campaign.
Conclusion
Jesy Nelson’s campaign for newborn SMA screening moved through several important stages in 2026.
After her twin daughters were diagnosed, she joined established SMA campaigners in calling for routine newborn testing.
In April, the NHS evaluation was brought forward to October 2026. Concerns then emerged that the first phase would cover only part of England.
Following further campaigning and parliamentary attention, the government announced in July that the evaluation would expand throughout England, with implementation continuing through 2027.
The programme remains an evidence-generating evaluation, but for families the practical change is significant: many more babies will have the opportunity to be identified before symptoms appear and referred rapidly for specialist assessment and treatment.
Sources and further reading
See the Department of Health and Social Care’s July 2026 announcement and the UK National Screening Committee’s information on the SMA in-service evaluation.
